Events Calendar

It will soon be 2 years since the first depot buprenorphine product (Buvidal®) was made available in Australia via a product familiarisation programme, 18 months since it was TGA approved, and a year since another depot buprenorphine product (Sublocade®) was PBS listed, for treatment of opioid dependence. While uptake of this treatment modality has been encouraging, a golden dawn of primary care, “office-based” treatment of opioid dependence has not arrived, despite the imperatives of the opioid epidemic and the COVID pandemic. In this seminar we look at challenges in the delivery of this treatment modality in a range of metropolitan and regional settings as a case study for the larger question of how to make addiction treatment more available to the people who need it, whoever and wherever they are. 

Presenters: 

Dr Jenny James VMO, GP Advice and Support Service, South Western Sydney Drug Health Services.

Penny Hall Clinical Nurse Consultant from Murrumbidgee Local Health District.

Ree McMillian Clinical Nurse Consultant, Western NSW Local Health District, providing OTP services from Dubbo and Orange to Bourke and beyond.

Anthony Ireson Clinical Nurse Consultant / Clinical Leader, Eurobodalla Drug & Alcohol Services

Followed by Q+A and panel discussion, with Addiction Medicine Specialists: Prof Paul Haber, Prof Nick Lintzeris and Dr Hester Wilson.

Spoiler Alert: “If we want get GPs to take on this kind of work, specialist addiction services should be offering something in return, such as seamless access to our services.”

Register for this Event here